A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07213791

Title field or adapter rule

{'original_value': 'A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.854449+00:00

Published At

2026-10-27T00:00:00+00:00

Record Updated At

2026-10-27

Source Retrieved At

2026-10-31T22:18:28.651351+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Ovarian Neoplasms", "Breast Neoplasms", "Pancreatic Intraductal Neoplasms", "Colorectal Neoplasms", "Esophageal Neoplasms", "Stomach Neoplasms", "Cholangiocarcinoma", "Advanced Solid Tumors"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07213791"

protocolSection.identificationModule.officialTitle

"A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Ovarian Neoplasms (protocolSection.conditionsModule.conditions)
• Breast Neoplasms (protocolSection.conditionsModule.conditions)
• Pancreatic Intraductal Neoplasms (protocolSection.conditionsModule.conditions)
• Colorectal Neoplasms (protocolSection.conditionsModule.conditions)
• Esophageal Neoplasms (protocolSection.conditionsModule.conditions)
• Stomach Neoplasms (protocolSection.conditionsModule.conditions)
• Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
• Advanced Solid Tumors (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['LY4337713 (Cohort A1)', 'LY4337713 (Cohort A2)', 'LY4337713 (Cohort B)', 'LY4337713 (Cohort C)', 'LY4337713 (Cohort D)', 'LY4337713 (Cohort E)'], 'description': 'Administered IV.', 'name': 'LY4337713', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• LY4337713 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.